ReviewMelanoma management2016
Biology and treatment of BRAF mutant metastatic melanoma.
Review in Melanoma management, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Real-world outcomes of advanced melanoma patients not represented in phase III trials.International journal of cancer · 2020Trial
- Widespread atypical UV-induced mutations form in single-stranded DNA.Science advances · 2026Article
- Recent Developments in the Diagnosis and Treatment of Disseminated and Rare Melanoma with Radiotheranostics.ACS pharmacology & translational science · 2026Review
- Genome-wide mutation spectra of canonical and atypical UV photoproducts in S. cerevisiae.Nucleic acids research · 2026Article
- Safety and efficacy of immune checkpoint inhibitors in patients with melanoma and pre-existing autoimmune conditions: a systematic review and meta-analysis.Immuno-oncology technology · 2026Review
- Epigenetic Modulators and Immunotherapy in Malignant Melanoma.Oncology research · 2026Review
- Antibiotic Exposure Does Not Impact Anti-BRAF/Anti-MEK Targeted Therapy Outcome in Patients with Advanced Melanoma.Current oncology (Toronto, Ont.) · 2025Article
- A case of anastomotic recurrence 12 years after intersphincteric resection for anorectal malignant melanoma.Clinical journal of gastroenterology · 2025Article
- Functionalized Cerium Oxide Nanoparticles Enhance Penetration into Melanoma Spheroids In Vivo through Angiogenesis.Advanced healthcare materials · 2025Article
- Advancements and Challenges in Personalized Therapy forJournal of clinical medicine · 2024Review
- Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma.Cancer treatment reviews · 2024Review
- Local Recurrent Melanoma Treated with BRAF and MEK Inhibitors Despite Adjuvant Anti-Programmed Cell Death Protein 1 Antibody Therapy.Annals of dermatology · 2023Article
- Contributions of replicative and translesion DNA polymerases to mutagenic bypass of canonical and atypical UV photoproducts.Nature communications · 2023Article
- PINK1 Immunoexpression Predicts Survival in Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.International journal of molecular sciences · 2023Article
- Retrospective review of outcomes associated with metastatic melanoma patients treated with 1st-line BRAF-targeted therapy.Pigment cell & melanoma research · 2022Article
- Article
- Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World Evidence.Journal of clinical medicine · 2022Article
- Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma.Journal of clinical medicine · 2022Review
- A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies.Cancer medicine · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BRAF inhibitors were among the first systemic therapies to show clinical benefit in metastatic melanoma. Here, we review the spectrum of BRAF mutations in melanoma, their role in oncogenesis, clinicopathological associations and response to treatment. The differing biology and clinical features of V600E- and V600K-mutated melanoma are outlined. The molecular changes associated with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.